HOME >> MEDICINE >> NEWS
Astrazeneca receives European approval for Seroquel; in bipolar mania

Sodertalje, Sweden, 13 October 2003 - AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) involving 14 European countries to extend the use of SEROQUEL (quetiapine) to the treatment of mania associated with bipolar disorder (manic-depressive illness). SEROQUEL is also under review for bipolar mania in the United States with the FDA and in the UK with the MHRA.

"This approval is great news for clinicians involved in the treatment of bipolar disorder," commented Dr. Eduard Vieta, Director of Research, Department of Psychiatry, University of Barcelona. "The results from the clinical trial programme confirm that SEROQUEL holds real benefits for clinicians looking to treat the symptoms of the disease while keeping side effects to a minimum. This is of particular importance when treating patients with bipolar disorder since they can be particularly sensitive to treatment side effects which can in turn have a negative impact on compliance with medication."

Bipolar disorder is a serious mental illness that affects approximately 3-4% of the adult population and is the sixth leading cause of disability in the world.1,2,3,4 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.5 This lack of compliance is strongly associated with the occurrence of side effects, therefore, a well tolerated and effective treatment is pivotal to the successful treatment of this condition.

Health authorities involved in the Mutual Recognition Procedure reviewed data from a comprehensive clinical trial programme in bipolar disorder undertaken by AstraZeneca, involving almost 1000 patients in 28 countries. The trials have delivered compelling results which confirm SEROQUEL to be an excellent first line therapy for the treatment of manic episodes associated with bipolar disorder.


'"/>

Contact: Rupert Doggett
rupert.doggett@shirehealthinternational.com
44-207-471-1500
Shire Health International
13-Oct-2003


Page: 1 2 3

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... 2017 (PRWEB) , ... July ... ... global provider of enterprise-grade IT operations analytics and application performance monitoring (APM) ... of world’s largest healthcare services providers. , According to Peter Ohrenberger, sales ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)... 2017  Mako Medical Laboratories partnered with Secretary Strickland, ... Assistance Fund (MFA) to bring 140 soldiers back home ... their families one last time before being deployed. Mako ... and logistics needed for these soldiers. "Mako Medical Laboratories ... families. We just wish we could bring them all ...
(Date:7/13/2017)... , July 13, 2017  Centurion Medical Products, a leader in ... DisImpactor ® fecal impaction removal device for hospice patient care. ... Centurion Medical ... Patient pain management and emotional comfort ... can help alleviate patient pain while preventing unneeded emergency department admission ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known as ... can quantify biological aging in a precise manner using the myDNAge ™ ... Horvath , a professor of human genetics and biostatistics at the ... of Public Health , Zymo Research,s proprietary DNAge ™ technology is ... ...
Breaking Medicine Technology:
Cached News: